Review
Environmental Sciences
Oliwia Zakerska-Banaszak, Liliana Lykowska-Szuber, Michal Walczak, Joanna Zuraszek, Aleksandra Zielinska, Marzena Skrzypczak-Zielinska
Summary: The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) has been confirmed for more than 50 years. Despite controversies over their cytotoxic properties and adverse effects, thiopurines are still widely used for maintaining remission in Crohn's disease and ulcerative colitis. Further research is needed to explore the modulation of thiopurine action in combination therapy and their interaction with the gut microbiota.
Review
Gastroenterology & Hepatology
Akira Andoh, Masahiro Kawahara, Takayuki Imai, Goichi Tatsumi, Osamu Inatomi, Yoichi Kakuta
Summary: The safety of thiopurine drugs during pregnancy remains uncertain, and NUDT15 genotyping may help prevent fetal toxicity effects.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Fenna M. Jansen, Lisa J. T. Smits, Pepijn W. A. Thomas, Dirk J. de Jong, Joany E. Kreijne, Willemijn A. van Dop, Nathan den Broeder, Frank Hoentjen
Summary: This single-center prospective cohort study evaluated the safety of a reduced 6-monthly monitoring strategy in steroid-free patients with quiescent IBD on stable dose of azathioprine, mercaptopurine, or thioguanine monotherapy. The primary outcome was thiopurine-related AEs requiring therapy adjustments during a follow-up period of 24 months. Three patients (4%) ceased thiopurine therapy due to thiopurine-related AEs, while no laboratory toxicity required therapy adjustments.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Medical Laboratory Technology
Sofia A. W. van Moorsel, Debbie S. Deben, Rob H. Creemers, Bjorn Winkens, Paul Bus, Marieke J. Pierik, Melek Simsek, Nanne K. H. de Boer, Adriaan A. van Bodegraven, Dennis R. Wong
Summary: This study aimed to validate and optimize predictive algorithms for thiopurine-associated hepatotoxicity, but found limited accuracy in predicting liver toxicity. Factors contributing to this outcome included changes in prescription behavior over time and lower dosages of MP being prescribed.
THERAPEUTIC DRUG MONITORING
(2022)
Article
Medicine, Research & Experimental
Zhong Xian, Jingzhuo Tian, Yushi Zhang, Jing Meng, Yong Zhao, Chunying Li, Yan Yi, Jiayin Han, Suyan Liu, Lianmei Wang, Chen Pan, Dunfang Wang, Fang Wang, Aihua Liang
Summary: The study found that compared to aristolochic acid I, aristolochic acid IVa has lower effects on nephrotoxicity, mutations, and tumorigenesis in mice, showing no obvious toxicity at certain doses and a lower mutagenicity and carcinogenic risk. Exposure to AAIVa may induce mild renal lesions but does not lead to severe damage or death like AAI.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Gastroenterology & Hepatology
Takahiko Toyonaga, Taku Kobayashi, Satoshi Kuronuma, Aito Ueno, Hiroki Kiyohara, Shinji Okabayashi, Osamu Takeuchi, Christopher P. F. Redfern, Hideki Terai, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Sally A. Coulthard, Yoichi Tanaka, Toshifumi Hibi
Summary: Polymorphisms in the NUDT15 gene may lead to increased DNA-incorporated deoxythioguanosine (dTG) accumulation in lymphocytes, causing cell apoptosis and thiopurine-induced leukopenia in patients with inflammatory bowel disease (IBD).
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Immunology
Shailesh Perdalkar, Pooja Basthi Mohan, Balaji Musunuri, Siddheesh Rajpurohit, Shiran Shetty, Krishnamurthy Bhat, Cannanore Ganesh Pai
Summary: This review provides evidence on the risk of COVID-19 infection and its severe prognosis in IBD patients on Thiopurine therapy. The results suggest that Thiopurine therapy is safe during the pandemic and does not increase the risk when used alone or in combination with other IBD drugs. Additionally, in vitro studies indicate that Thiopurine may have a potential therapeutic role against beta coronaviruses.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Zakaria Alameddine, Racha Abi Melhem, Reem Dimachkie, Hussein Rabah, Hamed Chehab, Michel El Khoury, Faris Qaqish, Dimitre Stefanov, Suzanne El-Sayegh
Summary: The use of biologic drugs is potentially associated with an increased risk of nephrolithiasis, particularly in the case of Vedolizumab.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Liang Ding, Fang-bin Zhang, Hui Liu, Xiang Gao, Hui-chang Bi, Ling Huang, Xue-ding Wang, Bai-li Chen, Yu Zhang, Chuanzhu Lv, Pin-jin Hu, Min Huang
Summary: The study revealed that patients with lower XO activity in thiopurine therapy are more likely to experience adverse effects, especially leukopenia. However, no significant correlation was found between XO activity and other adverse effects.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2021)
Article
Gastroenterology & Hepatology
Andree H. Koop, Paul M. Travers, Sahil Khanna, Darrell S. Pardi, Francis A. Farraye, Jana G. Hashash
Summary: This study evaluated the effectiveness of fidaxomicin in patients with inflammatory bowel disease and Clostridioides difficile infection. The results showed that 60.6% of patients responded to fidaxomicin treatment, and fecal microbiota transplantation was an effective therapy for non-responders.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Bhairavi Balram, Joshua Lubov, Yves Theoret, Waqqas Afif, Alain Bitton, Gary Wild, Peter L. Lakatos, Talat Bessissow
Summary: The study found that there is poor sustainability of clinical remission in IBD patients on thiopurine monotherapy, with only around a quarter of patients maintaining remission over a 5-year period. A significant proportion of patients discontinued thiopurines due to side effects or relapse.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Femke Crouwel, Ahmed B. Bayoumy, Chris J. J. Mulder, Job H. C. Peters, Paul J. Boekema, Luc J. J. Derijks, Sybrand Y. de Boer, Paul C. van de Meeberg, Ishfaq Ahmad, Hans J. C. Buiter, Nanne K. de Boer
Summary: This study aimed to evaluate the safety, effectiveness, and 12-month drug survival of first-line thioguanine therapy in thiopurine-naive patients with inflammatory bowel disease. The results showed that at 12 months, 53% of patients had a clinical response to thioguanine therapy and 86% of patients continued using thioguanine after 12 months. Only 8% of patients discontinued therapy due to adverse events.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Li Yang, Xiaomei Song, Yan Chen, Yue Li, Yubei Gu, Xinying Wang, Liangru Zhu, Min Zhi, Chunhui Ouyang, Hong Guo
Summary: The study found a significant difference between ideal and actual decision-making in IBD patients in China, with factors influencing ideal decision-making including income, education, illness severity, religiosity, importance of the treatment decision, employment situation, and occupation area; while factors affecting actual decision-making included age, illness severity, religiosity, employment situation, economic anxiety, concern about side effects, and importance of the treatment decision.
INFLAMMATORY BOWEL DISEASES
(2022)
Review
Oncology
Daniel Conceicao, Margarida R. Saraiva, Isadora Rosa, Isabel Claro
Summary: With the increase in life expectancy and the aging population, patients with inflammatory bowel disease (IBD) are being exposed to immunomodulating drugs for longer periods. This, as well as the recognized higher risk of some cancers in these patients, makes managing patients with IBD and current or past cancer more common. There is a need to balance the risks and benefits of different treatments in these patients.
Article
Gastroenterology & Hepatology
Grant E. Barber, Steven Hendler, Monica Choe, Kian Keyashian, Sarah Lechner, Berkeley N. Limketkai, David Limsui
Summary: This study assessed the efficacy of thiopurine monotherapy for mild-moderate inflammatory bowel diseases (IBD) and found that concurrent medications and disease severity were key factors affecting treatment outcomes during thiopurine therapy.
DIGESTIVE DISEASES AND SCIENCES
(2022)